Capricor Therapeutics said the FDA has issued a second complete response letter for deramiocel in Duchenne muscular dystrophy, rejecting the company’s application again after concluding that the data submitted did not establish “substantial evidence of effectiveness.” The agency also cited “certain other clinical deficiencies,” according to Capricor’s release.
The market reaction was immediate. Capricor shares fell nearly 80% after hours on Friday to $1.63, down from a closing price of $7.59. CEO Linda Marbán said the company was “deeply disappointed” for patients and families, while maintaining that deramiocel had been studied in two randomized, double-blind, placebo-controlled trials, HOPE-2 and HOPE-3, and that both met their primary endpoints. She said Capricor is reviewing the letter carefully and will outline next steps after that evaluation.
The Data
Deramiocel is made up of allogeneic cardiosphere-derived cells that, according to Capricor, have shown immunomodulatory and anti-fibrotic actions intended to help preserve skeletal and cardiac muscle function in muscular dystrophies including Duchenne muscular dystrophy.
Capricor’s more recent clinical case relied heavily on HOPE-3, a Phase 3 trial that randomized 106 patients with Duchenne muscular dystrophy to deramiocel or placebo for 12 months. In December 2025, the company reported that deramiocel produced statistically significant benefits in upper limb function, which it said met the trial’s primary endpoint. Capricor also said the therapy slowed decline in cardiac function as measured by left ventricular ejection fraction, meeting the secondary endpoint.
The FDA publicly read those results differently ahead of a July 29 advisory committee meeting. In briefing documents released before that meeting, the agency wrote that HOPE-3 “did not meet its pre-specified primary and secondary efficacy endpoints, showing no statistically significant difference between deramiocel and placebo at 12 months.” That gap between the company’s interpretation and the FDA’s interpretation is now central to the program’s problem: this is not a manufacturing-only dispute or a narrow filing issue, but a disagreement over whether the trial package demonstrates effectiveness at the standard the agency is applying.
The Road Here
This is Capricor’s second regulatory rejection for deramiocel. In July 2025, the FDA issued a complete response letter saying there was insufficient evidence to establish the therapy’s effectiveness for cardiomyopathy associated with Duchenne muscular dystrophy and also pointing to certain chemistry, manufacturing and controls deficiencies. Capricor responded at the time that it had already addressed those concerns in prior communications, but said the materials were not reviewed by the FDA because of the timing of the letter.
The review became unusually contentious. The first rejection reportedly followed the unilateral cancellation by then-CBER director Vinay Prasad of an advisory committee that had been scheduled by Nicole Verdun, then the director of the Center for Biologics Evaluation and Research’s Office of Therapeutic Products. Verdun and her deputy Rachael Anatol were both pushed out of the agency in June last year.
Capricor later shifted emphasis. The company had originally sought to market deramiocel for Duchenne muscular dystrophy cardiomyopathy, and that remained the main focus of the advisory committee discussion, where members voted 9-3 against approval. Capricor then pivoted to an upper limb function indication, which received a more positive discussion at the meeting, but that change was still not enough to secure approval.
Operationally, Capricor had already started tightening the business while preparing for either outcome. In September, the company cut around 10% of its workforce to align the organization with near-term priorities. Marbán also said on a Nov. 10 earnings call that if deramiocel were rejected, the company would assess whether another clinical trial could establish greater efficacy and or safety.
As of Sept. 30, Capricor reported around $198.5 million in cash, cash equivalents, restricted cash and marketable securities, which it said should fund planned operations for at least the next 12 months. That gives the company time to choose among limited options, but the second complete response letter suggests any path forward now depends less on procedural repair than on whether Capricor can produce evidence the FDA will accept as persuasive.




